[Determination of plasmatic beta2-microglobulin in benign and cancerous diseases (author's transl)]

The authors report on their experience of the beta2-microglobulin dosage in cancerous diseases and note an increase of its rate in 47% of the cases. A comparative study with certain benign diseases of the digestive tract shows that this dosage proves to be interesting.